VP16-213 and cyclophosphamide in advanced breast cancer. A phase II study.
Cancer Chemother Pharmacol
; 10(3): 154-7, 1983.
Article
em En
| MEDLINE
| ID: mdl-6861258
ABSTRACT
Twenty-seven patients with histologically proved advanced breast cancer were given VP 16-213 and cyclophosphamide. Twenty-one had shown resistance to other chemotherapy schedules and six had experienced relapse during adjuvant chemotherapy. There were four complete responses (15%) and seven partial responses (26%). Median survival was 61 weeks and median duration of response was 31.4 weeks. All patients experienced gastrointestinal toxicity and 22 patients (81%) showed bone marrow toxicity. This regimen is effective in advanced breast cancer resistant to other chemotherapy regimens.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Podofilotoxina
/
Neoplasias da Mama
/
Ciclofosfamida
/
Etoposídeo
Tipo de estudo:
Prognostic_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
1983
Tipo de documento:
Article